Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 01:00 | 2026-03-31 | ADCT | ADC Therapeutics SA | Redmile Group, LLC | 10% owner | Pharmaceutical Preparations | SALE | $3.34 | 5,880,415 | $19,636,470 | 10,265,297 | -36.4% |
| 2026-04-03 00:26 | 2026-04-02 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $39.92 | 30,000 | $1,197,489 | 183,316 | -14.1% |
| 2026-04-03 00:09 | 2026-04-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Officer; President, R&D | Pharmaceutical Preparations | OPT+S | $21.20 | 27,000 | $572,478 | 112,622 | -19.3% |
| 2026-04-02 23:43 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | Pharmaceutical Preparations | SALE | $202.23 | 467 | $94,440 | 42,253 | -1.1% |
| 2026-04-02 23:43 | 2026-04-02 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer; EVP, Chief Human Resources Ofc | Pharmaceutical Preparations | SALE | $74.05 | 6,193 | $458,613 | 16,348 | -27.5% |
| 2026-04-02 23:43 | 2026-04-01 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | Pharmaceutical Preparations | OPT+S | $75.55 | 22,321 | $1,686,302 | 11,014 | -67.0% |
| 2026-04-02 23:16 | 2026-04-01 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer; President and COO | Biological Products, (No Diagnostic Substances) | OPT+S | $14.53 | 38,120 | $553,693 | 447,202 | -7.9% |
| 2026-04-02 22:53 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Director | Pharmaceutical Preparations | OPT+S | $25.00 | 3,000 | $75,000 | 6,200 | -32.6% |
| 2026-04-02 22:54 | 2026-03-31 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $26.27 | 75,000 | $1,970,520 | 705,051 | -9.6% |
| 2026-04-02 22:56 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer; CLO & Secretary | Pharmaceutical Preparations | OPT+S | $201.24 | 5,000 | $1,006,224 | 41,382 | -10.8% |
| 2026-04-02 23:02 | 2026-04-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer; Chief Legal Officer | Pharmaceutical Preparations | SALE | $15.24 | 8,148 | $124,149 | 26,453 | -23.5% |
| 2026-04-02 22:28 | 2026-04-01 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer; PRESIDENT AND CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $64.81 | 40,000 | $2,592,236 | 767,780 | -5.0% |
| 2026-04-02 22:15 | 2026-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Officer; Chief Medical Officer | Pharmaceutical Preparations | SALE | $52.75 | 942 | $49,693 | 105,673 | -0.9% |
| 2026-04-02 22:19 | 2026-04-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $20.97 | 4,683 | $98,203 | 80,351 | -5.5% |
| 2026-04-02 21:02 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Lu Hongbo | Director | Pharmaceutical Preparations | BUY | $18.63 | 3,768 | $70,198 | 426,736 | +0.9% |
| 2026-04-02 21:05 | 2026-04-02 | LPCN | Lipocine Inc. | Patel Mahesh V. | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $2.02 | 25,000 | $50,500 | 135,679 | +22.6% |
| 2026-04-02 20:48 | 2026-03-31 | MLTX | MoonLake Immunotherapeutics | BVF PARTNERS L P/IL | Director, 10% owner | Pharmaceutical Preparations | SALE | $16.79 | 3,750,000 | $62,962,500 | 1,039,238 | -78.3% |
| 2026-04-02 20:34 | 2026-03-31 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $585.76 | 9,500 | $5,564,709 | 40,513 | -19.0% |
| 2026-04-02 20:35 | 2026-04-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $581.63 | 9,500 | $5,525,526 | 40,513 | -19.0% |
| 2026-04-02 20:36 | 2026-04-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Pharmaceutical Preparations | OPT+S | $565.87 | 8,300 | $4,696,690 | 45,172 | -15.5% |
| 2026-04-02 20:05 | 2026-04-01 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Officer; Chief R&D Officer | Biological Products, (No Diagnostic Substances) | SALE | $5.26 | 22,598 | $118,865 | 95,961 | -19.1% |
| 2026-04-02 20:05 | 2026-04-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $6.31 | 10,946 | $69,069 | 113,856 | -8.8% |
| 2026-04-02 17:01 | 2026-04-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | Officer; CMO | Pharmaceutical Preparations | OPT+S | $32.31 | 28,662 | $926,095 | 9,597 | -74.9% |
| 2026-04-02 16:00 | 2026-03-31 | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% owner | Pharmaceutical Preparations | BUY | $10.60 | 520 | $5,512 | 1,538,296 | +0.0% |
| 2026-04-02 14:46 | 2026-04-01 | VIR | Vir Biotechnology, Inc. | SATO VICKI L | Director | Biological Products, (No Diagnostic Substances) | SALE | $9.07 | 22,000 | $199,617 | 1,100,391 | -2.0% |
| 2026-04-02 12:01 | 2026-04-01 | SCYX | SCYNEXIS INC | Angulo Gonzalez David | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $0.00 | 108,695 | $0 | 1,357,126 | +8.7% |
| 2026-04-01 20:12 | 2026-03-30 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer; CSBO | Biological Products, (No Diagnostic Substances) | OPT+S | $29.34 | 7,500 | $220,019 | 10,503 | -41.7% |
| 2026-04-01 21:08 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Officer; Chief Development Officer | Pharmaceutical Preparations | BUY | $2.54 | 2,107 | $5,341 | 3,711 | +131.4% |
| 2026-04-01 20:27 | 2026-03-30 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Director | Pharmaceutical Preparations | BUY | $17.08 | 2,000 | $34,160 | 15,500 | +14.8% |
| 2026-04-02 01:28 | 2026-03-30 | ANAB | ANAPTYSBIO, INC | Schmid John P. | Director | Pharmaceutical Preparations | SALE | $56.11 | 20,645 | $1,158,451 | 31,622 | -39.5% |
| 2026-04-02 00:00 | 2026-03-31 | CAPR | CAPRICOR THERAPEUTICS, INC. | Bergmann Anthony | Officer; CHIEF FINANCIAL OFFICER | Pharmaceutical Preparations | OPT+S | $30.13 | 25,000 | $753,153 | 8,223 | -75.2% |
| 2026-04-02 00:00 | 2026-03-31 | CAPR | CAPRICOR THERAPEUTICS, INC. | Sabar Karimah Es | Director | Pharmaceutical Preparations | OPT+S | $30.57 | 115,000 | $3,515,470 | 0 | -100.0% |
| 2026-04-02 00:00 | 2026-03-31 | CAPR | CAPRICOR THERAPEUTICS, INC. | Krasney Karen | Officer; EVP, GENERAL COUNSEL | Pharmaceutical Preparations | OPT+S | $30.12 | 25,000 | $752,935 | 30,547 | -45.0% |
| 2026-04-01 22:58 | 2026-04-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer; EVP R&D, Chief Medical Officer | Pharmaceutical Preparations | OPT+S | $35.51 | 9,000 | $319,604 | 85,389 | -9.5% |
| 2026-04-01 23:00 | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer; Chief Operating Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $85.43 | 22,240 | $1,900,048 | 61,202 | -26.7% |
| 2026-04-01 23:00 | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $85.39 | 12,000 | $1,024,661 | 0 | -100.0% |
| 2026-04-01 22:32 | 2026-03-30 | BEAM | Beam Therapeutics Inc. | Evans John M. | Director, Officer; CEO | Biological Products, (No Diagnostic Substances) | OPT+S | $22.57 | 50,000 | $1,128,315 | 986,667 | -4.8% |
| 2026-04-01 21:54 | 2026-03-30 | XERS | Xeris Biopharma Holdings, Inc. | Brady James Aloysius | Director | Pharmaceutical Preparations | SALE | $5.54 | 10,834 | $60,036 | 89,166 | -10.8% |
| 2026-04-01 21:26 | 2026-03-31 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Soteropoulos Paula | Director | Pharmaceutical Preparations | OPT+S | $80.11 | 599 | $47,986 | 0 | -100.0% |
| 2026-04-01 21:26 | 2026-03-31 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Savitz Ryan | Officer; EVP, CFO & CBO | Pharmaceutical Preparations | OPT+S | $83.00 | 114,367 | $9,492,598 | 0 | -100.0% |
| 2026-04-01 21:09 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer; Chief Administrative Officer | Pharmaceutical Preparations | BUY | $2.54 | 1,854 | $4,700 | 3,110 | +147.6% |
| 2026-04-01 21:10 | 2026-04-01 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | Pharmaceutical Preparations | SALE | $4.97 | 4,278 | $21,262 | 426,816 | -1.0% |
| 2026-04-01 21:11 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer; Chief Business - Strategy Off | Pharmaceutical Preparations | BUY | $2.54 | 1,603 | $4,064 | 3,356 | +91.4% |
| 2026-04-01 21:15 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | BUY | $2.54 | 2,136 | $5,415 | 3,649 | +141.2% |
| 2026-04-01 21:17 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Pannu Geraldine | Director | Pharmaceutical Preparations | BUY | $2.54 | 2,072 | $5,253 | 2,188 | +1,786.2% |
| 2026-04-01 21:18 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer; Chief Financial Officer | Pharmaceutical Preparations | BUY | $2.54 | 2,324 | $5,891 | 2,324 | +100.0% |
| 2026-04-01 21:20 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer; Pres. Research & Development | Pharmaceutical Preparations | BUY | $2.54 | 1,810 | $4,588 | 10,562 | +20.7% |
| 2026-04-01 21:06 | 2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Baluch Khoso | Director | Pharmaceutical Preparations | BUY | $2.54 | 2,269 | $5,752 | 2,325 | +4,051.8% |
| 2026-04-01 20:30 | 2026-03-31 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Director | Pharmaceutical Preparations | BUY | $3.45 | 1,160,000 | $4,002,000 | 13,160,000 | +9.7% |
| 2026-04-01 20:30 | 2026-03-31 | ZBIO | Zenas BioPharma, Inc. | Fairmount Funds Management LLC | Director | Pharmaceutical Preparations | BUY | $20.00 | 150,000 | $3,000,000 | 2,359,025 | +6.8% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.